Mechanisms of daptomycin resistance in Staphylococcus aureus

被引:73
作者
Kaatz, Glenn W. [1 ]
Lundstrom, Tammy S.
Seo, Susan M.
机构
[1] Wayne State Univ, Sch Med, John D Dingell Dept Vet Affairs Med Ctr, Detroit, MI 48201 USA
[2] Wayne State Univ, Sch Med, Div Infect Dis, Dept Internal Med, Detroit, MI 48201 USA
关键词
Staphylococcus aureus; daptomycin; antimicrobial resistance;
D O I
10.1016/j.ijantimicag.2006.05.030
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Daptomycin resistance in Staphylococcus aureus emerged during therapy of tricuspid endocarditis. Susceptibility to daptomycin of the parent strain (SA-675), other daptomycin-susceptible strains and the non-susceptible mutant (SA-684) was heterogeneous; however, subpopulations growing at concentrations above the minimum inhibitory concentration (MIC) were not stably resistant. Stable resistance was produced only by serial passage on daptomycin-containing media. Daptomycin dissipated the membrane potential of SA-675 but not SA-684, which also lost an 81 kDa membrane protein. Whole cells and membranes of SA-684 bound a reduced amount of daptomycin. Reduced drug binding in SA-684 correlates with daptomycin resistance, possibly as a result of the loss of a membrane protein 'chaperone' with which daptomycin interacts. Heterogeneity of daptomycin MICs in susceptible strains may be an important factor in the development of stable, clinically relevant resistance. (c) 2006 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:280 / 287
页数:8
相关论文
共 41 条
[1]   In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model [J].
Akins, RL ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (07) :1925-1929
[2]   DAPTOMYCIN DISRUPTS MEMBRANE-POTENTIAL IN GROWING STAPHYLOCOCCUS-AUREUS [J].
ALBORN, WE ;
ALLEN, NE ;
PRESTON, DA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (11) :2282-2287
[3]   INHIBITION OF MEMBRANE POTENTIAL-DEPENDENT AMINO-ACID-TRANSPORT BY DAPTOMYCIN [J].
ALLEN, NE ;
ALBORN, WE ;
HOBBS, JN .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (12) :2639-2642
[4]  
[Anonymous], 2003, NCCLS Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, V6th
[5]   RAMOPLANIN (A-16686), A NEW GLYCOLIPODEPSIPEPTIDE ANTIBIOTIC .3. STRUCTURE ELUCIDATION [J].
CIABATTI, R ;
KETTENRING, JK ;
WINTERS, G ;
TUAN, G ;
ZERILLI, L ;
CAVALLERI, B .
JOURNAL OF ANTIBIOTICS, 1989, 42 (02) :254-267
[6]   Genetics of glycopeptide resistance in Gram-positive pathogens [J].
Courvalin, P .
INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, 2005, 294 (08) :479-486
[7]   Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus [J].
Cui, LZ ;
Tominaga, E ;
Neoh, HM ;
Hiramatsu, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (03) :1079-1082
[8]   Applications of the bacteriocin, nisin [J].
DelvesBroughton, J ;
Blackburn, P ;
Evans, RJ ;
Hugenholtz, J .
ANTONIE VAN LEEUWENHOEK INTERNATIONAL JOURNAL OF GENERAL AND MOLECULAR MICROBIOLOGY, 1996, 69 (02) :193-202
[9]   Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections [J].
Eisenstein, BI .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (09) :1159-1169
[10]   INVITRO ACTIVITY AND MECHANISM OF ACTION OF A21978C1, A NOVEL CYCLIC LIPOPEPTIDE ANTIBIOTIC [J].
ELIOPOULOS, GM ;
THAUVIN, C ;
GERSON, B ;
MOELLERING, RC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 27 (03) :357-362